Objective: To evaluate the therapeutical effect of endostatin adenoviral vector on malignant ascites and compare it with the combined effect of ad-endostatin and DDP.
Methods: We transfected SKOV3 cells with ad-endostatin to inhibit human umbilical vein endothelial cells (HUVEC) proliferation. Then we administered ad-endostatin intraperitoneally in BALB/c mice to detect the serum endostatin expression and in the mice with malignant ascites to evaluate the therapeutic efficacy.
Results: Recombinant endostatin inhibited HUVEC proliferation. Endostatin was expressed in serum after intraperitoneal injection of ad-endostatin. The effects of endostatin on inhibition of the ascites accumulation and peritoneal capillary permeability, on demotion of VEGF protein level and microvascular density in tumor tissues, on reduction of the number of red cells and tumor cells counted in malignant ascites, and on prolongation of mice survival were significant in two different malignant ascites. Furthermore, the combination of ad-endostatin with DDP increased the therapeutic efficacy.
Conclusion: These data suggested that endostatin gene therapy may represent a potential new treatment for malignant ascites, and the therapeutic efficacy can be enhanced by a combination of ad-endostatin with chemotherapy.